Skiplink Navigation

Main Features

EU gives green light to Serono MS drug

Serono will be able to market its MS drug in the European Union

(Keystone Archive)

The Geneva-based biotechnology group, Serono, has been given European Union approval for its multiple sclerosis (MS) drug, Rebif.

The company said the EU had also recommended the treatment as a first-line therapy for patients with relapsing-remitting MS, the most common form of the disease.

Serono said the Commission's approval was based on a four-year study, which provided clinical evidence that a high dose of Rebif administered as early as possible after the onset of the disease "significantly improves the long-term outlook for the patient".

Serono said Rebif is the only interferon beta product to have gained full approval by the Commission.

The company also announced that it had launched two fertility products in the United States,Ovdrel and Cetrotide.

swissinfo with agencies


Neuer Inhalt

Horizontal Line

swissinfo EN

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

Join us on Facebook!

subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.

Click here to see more newsletters